Clinical Trials

Singapore HSA Approves GSK’s Blenrep Combinations for Relapsed or Refractory Multiple Myeloma

Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based triplet in DREAMM-7 Blenrep, a f...

 August 19, 2026 | News

OncoC4 Doses First Patient in Phase I Trial of neoCD24-Targeting T-Cell Engager ONC-783

— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous f...

 August 19, 2026 | News

Connext Completes Phase 2 Enrollment of CNT201 for Dupuytren’s Contracture

 All 56 planned participants enrolled approximately five months after first patient dosing - Topline Phase 2 data expected in late 2026 - Positive d...

 August 19, 2026 | News

JW Pharmaceutical’s Epaminurad Shows Statistical Superiority in Phase III Gout Trial

-JW Pharmaceutical (KRX:001060) announced that the multinational Phase 3 clinical trial of its gout treatment candidate ‘Epaminurad (code name U...

 August 18, 2026 | News

AbelZeta Secures US FDA IND Clearance for Bispecific CAR-T Therapy C-CAR039 in Large B-cell Lymphoma

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovati...

 August 18, 2026 | News

ArkBio Advances Ziresovir into US Phase II Trial for Severe RSV in Infants

Shanghai Ark Biopharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II cli...

 August 17, 2026 | News

China Approves Geneseeq’s PanTRKare as Companion Diagnostic for VELMARTO

NMPA granted approval to Geneseeq's PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectini...

 August 14, 2026 | News

ArkBio’s Long-Acting Influenza Candidate AK0406 Secures IND Approval in China

Shanghai Ark Biopharmaceutical Co., Ltd. announced that the Investigational New Drug (IND) application for AK0406 injection, the company's first long-actin...

 August 14, 2026 | News

Asia-Pacific’s Geroscience Paradox: Plenty of Ageing Research, Just Five Clinical Assets

It is not a settled matter. It is a claim that has been made continuously for four years without anyone publishing the test they applied. So we wrote a tes...

 August 13, 2026 | Analysis

Datasea Lists NeuroVibe Biofeedback System with US FDA as Class II 510(k)-Exempt Device

Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company focused on acoustic high-tech and AI multimodal digit...

 August 13, 2026 | News

Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema

 Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializin...

 August 12, 2026 | News

Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced Breast Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) eval...

 August 11, 2026 | News

RiboX Secures FDA IND Clearance for World’s First Circular RNA-Based In Vivo CAR-T Therapy

The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy ...

 August 10, 2026 | News

Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic

Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen...

 August 07, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close